Baxter International Inc. logo

Baxter International Inc.

BAX | NYSE
Chart Builder DCF Calculator
$23.00
-$0.50 (-2.13%)
At close: Oct 30, 2026, 4:00 PM ET
$23.17
+$0.17 (+0.74%)
Pre-market: Nov 2, 2026, 7:33 AM ET

Company Profile

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Key Executives

Name Position
Andrew Hider Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director
Anita A. Zielinski Senior Vice President, Interim Chief Financial Officer, Chief Accounting Officer & Controller
Charles Patel Senior Vice President & Chief Information Officer
Adriana Guiry Senior Vice President of Baxter Growth & Performance System
Cynthia Carlisle Executive Vice President & Chief Human Resources Officer
David S. Rosenbloom Executive Vice President & General Counsel
James Teaff President of Care & Connectivity Solutions
James W. Borzi Executive Vice President & Chief Supply Chain Officer
Kevin Moran Vice President & Head of Investor Relations
Maria Soriano Group President of Infusion Therapies & Platforms
Piero Novello Senior Vice President and President of International
Scott Kaplan Senior Vice President of Quality, Regulatory & Patient Safety
Stacey Eisen SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation
Steven Wallace President of Advanced Surgery & Commercial Excellence

Latest SEC Filings

Date Type Title
Oct 02, 2026 3 Filing
Sep 18, 2026 3 Filing
Sep 03, 2026 4 Filing
Sep 03, 2026 4 Filing
Sep 03, 2026 4 Filing
Aug 19, 2026 8-K Current Report
Aug 18, 2026 8-K Current Report
Aug 04, 2026 8-K Current Report
Aug 04, 2026 8-K Current Report
Jul 30, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Baxter International Inc.
Baxter International Inc. logo
Country United States
IPO Date Oct 27, 1981
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 37,500
CEO Andrew Hider

Contact Details

One Baxter Parkway Deerfield, Illinois 60015 United States

Stock Details

Ticker Symbol BAX
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000010456
CUSIP Number 071813109
ISIN Number US0718131099
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.